Forge Your Future with Us:

At Forge Biologics, we believe in turning bold ideas into life-changing realities. Our mission is simple yet powerful: to enable access to life-changing gene therapies and help bring them from ideas into reality. We partner with scientists, physicians, biotech and pharma innovators, and patient communities — all united by one goal: improving lives. If you’re driven by purpose and excited to make a tangible impact, this is where your journey begins.

Our team works out of The Hearth, a state-of-the-art, 200,000-square-foot cGMP facility in Columbus, Ohio. Here, you won’t just watch innovation happen — you’ll be part of it. Whether you’re scaling AAV manufacturing, collaborating on cutting-edge therapies, or supporting complex technical projects, you’ll play a key role in bringing hope to patients with genetic diseases.

What sets Forge apart is our culture of H.O.P.E. We are hardworking, showing up each day with determination and grit. We are open, creating a space where ideas flow freely, and every voice is valued. We are purpose-driven, with every task directly tied to changing lives. And we are engaged, energized by the challenges we face and the milestones we achieve together.

At Forge, your growth matters. We’re committed to helping you expand your skills, take on new challenges, and develop your career through mentorship, hands-on learning, and opportunities for advancement. Our people are our greatest investment, and we’re proud to see team members grow with us.

If you’re ready to use your talent to help deliver hope to patients around the world, join us — and be part of something bigger than yourself.

About The Role:

The GMP Equipment Monitoring Technician – 3rd shift role, plays a critical role in maintaining manufacturing readiness and operational continuity in a GMP-regulated AAV gene therapy environment. This position is responsible for monitoring complex manufacturing equipment such as bioreactors and chromatography skids, supporting facility monitoring activities, maintaining cleanroom readiness, and assisting with equipment and manufacturing area setup and cleanup. This role ensures that equipment and facility conditions remain within operational standards while supporting day-to-day GMP manufacturing activities.

Responsibilities:

Monitor and support operation of complex GMP manufacturing equipment, including bioreactors and chromatography skids, ensuring systems remain within defined operating parameters.
Perform routine facility and equipment monitoring activities, documenting status and alarms in accordance with GMP requirements and SOPs.
Support manufacturing operations by assisting with operations extending into night shift; equipment setup, changeover, and cleanup activities before and after production runs.
Stock, stage, and organize materials, consumables, and supplies required for manufacturing operations to ensure readiness and efficiency.
Support Facilities and Engineering (F&E) activities, including coordination of equipment readiness, maintenance support, and escalation of issues as needed.
Assist in troubleshooting routine equipment and facility issues and escalate complex problems to appropriate technical or engineering teams.
Maintain accurate and timely GMP documentation, including logbooks, monitoring records, and manufacturing support documentation.
Collaborate with GMP Manufacturing, F&E, Quality Assurance (QA), and Quality Control (QC) teams to support production continuity and compliance.
Follow GMP gowning requirements and cleanroom protocols to maintain contamination control standards.
May assist in continuous improvement initiatives focused on equipment reliability, cleanroom efficiency, and operational effectiveness.
Follow all safety procedures and maintain a clean, organized, and compliant work environment.

Qualifications:

Associate’s degree or technical certification in a scientific or engineering-related field (or equivalent professional experience).
Experience troubleshooting equipment within a manufacturing, laboratory, or other regulated environment.
Ability to diagnose, troubleshoot, and resolve equipment issues in a timely manner.
Excellent analytical and problem-solving skills to diagnose and resolve equipment performance issues efficiently.
Strong documentation skills with attention to detail for maintaining logbooks, audit records, and compliance documentation.
Ability to work independently and collaboratively across cross-functional teams, including Process Development, Quality, Facilities & Engineering.
Ability to work in loud noise environments and in Personal Protective Equipment (PPE) and Clean Room gowning attire as needed.
Ability to work flexible 3rd shift hours, typically between 9pm and 7am, based on GMP production run schedules.

Preferred Skills:

Exposure to GMP-regulated cell or gene therapy manufacturing environments.
Experience supporting Facilities & Engineering (F&E) activities or maintenance coordination.
Understanding of alarm monitoring, equipment status tracking, and manufacturing readiness workflows.
Experience with cleanroom cleaning, staging, and material handling in a regulated environment.

This job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee. Duties, responsibilities and activities may change, or new ones may be assigned.

Work Environment and Physical Demands

This position works in both a laboratory environment and a typical office environment where the physical work demands will vary depending on the specific tasks and duties required of the job. The employee will be stationary (standing/sitting) for extended periods of time. Employees regularly wear personal protective equipment based on the task being performed. Must be able to work in a confined space, such as a clean room or laboratory environment. Ability to identify small details within the field of vision, distinguish between different colors, and accurately identify objects within a specific area. 

Forge Biologics is an equal opportunity employer dedicated to building an inclusive and diverse workforce. Forge Biologics, provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.

We’ve Got You Covered:

At Forge Biologics, we believe our people deserve to be taken care of – in and out of the workplace. We’ve built a comprehensive compensation and benefits package designed to help you thrive, grow, and feel valued every step of the way:

Health from day one

Health, dental and vision insurance start your first day – with 90% of premiums covered for you and your family.

Time to recharge

A competitive paid time off plan – because rest fuels innovation.
12 weeks of fully paid parental leave so you can focus on family when it matters most.

Rewarding your impact

Annual bonus opportunities for all full-time team members.
401(k) with company match to help you plan for the future.
Special employee discounts, including childcare and dependent care savings.

Your wellness, supported

Onsite fitness facility at The Hearth.
Mental health counseling and financial planning services through our Employee Assistance Program.
Employer-paid short and long-term disability coverage to protect your peace of mind.

Fuel for your workday

A fully stocked kitchen with free snacks and beverages – we keep you energized and ready for what’s next.

Grow with us

Ongoing professional development resources, training, and mentorship programs to help you build your care and grow within Forge.

About the company

Forge Biologics provides end-to-end development and manufacturing for gene therapies, using its gene therapy development engine to move ideas from the lab into scalable production. It focuses on AAV-based therapies and operates from Hearth, a large cGMP facility designed for manufacturing at scale. Revenue comes from offering manufacturing services to other companies and researchers, while also developing its own therapies for potential future products. Its goal is to become a leading, integrated manufacturing partner for gene therapies, helping rare genetic-disease programs reach the clinic and market.

Company Size

201-500

Company Stage

Acquired

Total Funding

$250M

Headquarters

Columbus, Ohio

Founded

2020

Get referred to Forge Biologics

See people who can refer or advise you

Simplify's Take

What believers are saying

Forge signed TECPR2, Restore Vision, Skylark, and Epicrispr partnerships in 2026.
Restore Vision's July 2026 material supports Phase 1/2 retinitis pigmentosa trials in Japan.
Epicrispr's May 2026 material supports first-in-human FSHD trials across U.S., New Zealand, Australia.

What critics are saying

Forge filed a trademark dispute against Intricon on August 19, 2026.
Forge sells mostly to preclinical and early clinical programs; cancellations hit utilization fast.
No approved Forge-owned therapy exists; one failed commercial-scale campaign cripples margin expansion.

What makes Forge Biologics unique

Forge runs Columbus Hearth: 20 cGMP suites and 20,000 liters for AAV scale.
FUEL platform claims 6-22x productivity gains and supports all serotypes, including novel capsids.
Ajinomoto ownership since December 2023 adds global pharma integration and financing stability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
401(k) Company Match
Annual Bonus
Paid Parental Leave
Employee Assistance Program
Wellness Program
Onsite Fitness Facility

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

11%

Contract Pharma

Sep 29th, 2026

Forge, TECPR2 Research Foundation strike AAV gene therapy development, manufacturing partnership.

Forge, TECPR2 Research Foundation strike AAV gene therapy development, manufacturing partnership. Forge will provide process and analytical development, and leverage its proprietary manufacturing efficiency platform. September 29, 2026 Content Marketing Editor Editor's Take: This partnership helps advance a gene therapy program for an ultra-rare condition that primarily affects children. Forge Biologics and the TECPR2 Research Foundation announced a development and manufacturing partnership to advance an adeno-associated virus (AAV) therapy. TECPR2-related disorder is an ultra-rare, genetic, neurodevelopmental and neurodegenerative condition caused by pathogenic variants in the TECPR2 gene. It is classified as a childhood disease, also known as SPG49 or HSAN9. More TECPR2 details. Importantly, TECPR2 has a role in autophagy - a cellular process that degrades or recycles damaged or unnecessary cellular components. The disease can cause certain developmental delays and progressive neurological complications, including respiratory dysfunction, and can be fatal. The investigational AAV gene therapy, then, uses an AAV vector to deliver a functional copy of the TECPR2 gene. This ideally addresses the underlying genetic cause of the disease. How Forge helps. The terms of the partnership charge Forge with providing process development, analytical development and qualification, and manufacturing services. Included therein is the manufacture and release of material for toxicology studies that support the program's continuing advancement. A research team at the University of Texas (UT) Southwestern Medical Center is helping advance the program toward clinical development. Forge is leveraging its proprietary Fuel platform, which helps drive manufacturing efficiencies. Gene therapy possibilities. "This partnership is a shared belief in what gene therapy can make possible," Forge President and CEO John Maslowski said. "For programs like TECPR2, making the most of every manufacturing run is critical. We are honored to bring our manufacturing technology and expertise to a program that is so deeply personal." "For our families, this has never simply been a research program," TECPR2 Research Foundation Co-Founder David Ogman said. "It began with a few children and a commitment to do everything we could to create a path forward... These scientists and partners believe, as we do, that children with ultra-rare diseases deserve the same opportunities as anyone else." Forge Biologics is a member of Ajinomoto Bio-Pharma Services. Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Business Wire

Jun 16th, 2026

Skylark Bio and Forge Biologics announce strategic AAV development and cGMP manufacturing partnership supporting Skylark's clinical development.

Skylark Bio and Forge Biologics announce strategic AAV development and cGMP manufacturing partnership supporting Skylark's clinical development. Skylark Bio is leveraging Forge's AAV FUEL(TM) platform technologies and cGMP manufacturing services to advance its gene therapy for patients with genetic hearing loss CAMBRIDGE, Mass. & COLUMBUS, Ohio-(BUSINESS WIRE)-Skylark Bio ("Skylark"), a clinical-stage biotechnology company developing targeted genetic medicines for hearing loss, and Forge Biologics ("Forge"), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a strategic AAV development and cGMP manufacturing partnership. "Forge provides the partnership we need to confidently advance our research into clinical development." Share Under the partnership, Forge is providing Skylark with process development, current good manufacturing practice (cGMP) manufacturing, and analytical development services. Skylark is also leveraging Forge's proprietary FUEL(TM) platform technologies, including its HEK293 suspension Ignition Cells(TM) and pEMBR(TM) 2.0 adenovirus helper plasmid. All development and manufacturing activities are being conducted at the Hearth, Forge's 200,000-square-foot gene therapy development and manufacturing facility in Columbus, Ohio. "As we enter the clinic with our lead program, Skylark needs a manufacturing partner who shares our commitment to excellence," said Jodi Cook, Ph.D., President and Chief Executive Officer of Skylark. "Forge provides the partnership we need to confidently advance our research into clinical development. Their end-to-end AAV gene therapy manufacturing capabilities provide exactly the foundation we're looking for, and they've integrated seamlessly with our team to help ensure our therapies are manufactured with the rigor and care that patients deserve." Skylark's lead program, SKY-GJB2, is currently being evaluated in a Phase 1/2 clinical trial for GJB2-related hearing loss, the leading genetic cause of inherited hearing loss worldwide. The investigational AAV gene therapy is designed to deliver a functional copy of the GJB2 gene directly to cells in the inner ear affected by disease-causing mutations, with the potential to address the underlying genetic cause of hearing loss. SKY-GJB2 leverages Skylark's proprietary capsid platform, which is engineered for targeted, low-dose delivery and durable gene expression. "At the heart of our collaboration with Skylark is a shared mission to bring meaningful treatment options to patients," said John Maslowski, President and Chief Executive Officer of Forge. "This partnership reflects our focus on improving how gene therapies are made so more promising medicines can reach those who need them. By combining our platform technologies with manufacturing expertise, we are proud to support Skylark as it advances its gene therapy program through clinical development." About Skylark Bio Skylark Bio is a clinical-stage genetic medicine company developing precision, locally delivered gene therapies for monogenic diseases, with the potential to meaningfully improve patient outcomes and quality of life. The company's lead program, SKY-GJB2, is in a Phase 1/2 first-in-human clinical trial for GJB2-related hearing loss - the leading cause of inherited hearing loss worldwide. A second program targeting SLC26A4-related hearing loss (Pendrin) is advancing through IND-enabling studies. Built on a proprietary capsid engineered for broad transduction, Skylark's platform enables targeted, micro-dose delivery with cell-specific expression control and the potential for durable benefit in non-dividing cells of interest. The company is led by a team with deep expertise in gene therapy and supported by world-class advisors as it expands its platform into additional hearing and CNS indications. For more information, visit Skylarkbio.com and follow Avistatx on LinkedIn. About Forge Biologics Forge Biologics, a member of Ajinomoto Bio-Pharma Services, is a gene therapy contract development and manufacturing organization (CDMO) enabling access to life-changing gene therapies by bringing them from concept to reality. Forge's 200,000 square foot facility, the Hearth, is headquartered in Columbus, Ohio, and houses 20 custom-designed cGMP suites with 20,000L of bioreactor capacity. Forge's end-to-end, scalable plasmid and AAV manufacturing services include research-grade manufacturing, process and analytical development, cGMP manufacturing, fill-finish, and integrated regulatory support to help accelerate the timelines of transformative medicines for patients with genetic diseases. To learn more, visit www.forgebiologics.com. Contacts. Media Inquiries Skylark Bio: Susan Sharpe Linnden Communications [email protected] Forge Biologics: Media Marina Corleto Associate Director, Marketing & Communications [email protected] Client Development Taleen Barsoumian Senior Vice President, Client Development [email protected] More News From Forge Biologics COLUMBUS, Ohio-( BUSINESS WIRE )-Forge Biologics, ("Forge"), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver seven presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, taking place May 11-15, 2026, in Boston. The presentations include two technical sessions, co-chairing an oral abstract session, and four scientific posters. "As the gene therapy field enters a crit... SAN FRANCISCO & COLUMBUS, Ohio-( BUSINESS WIRE )-Epicrispr Biotechnologies ("Epicrispr"), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics ("Forge"), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to support the development and manufacturing of EPI-321, Epicrispr's investigational AAV gene therapy for facioscapulohumeral muscular dystrophy (FSHD). Through this collaboration... COLUMBUS, Ohio-( BUSINESS WIRE )-Forge Biologics, ("Forge"), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced it has achieved My Green Lab(R) Certification, the global gold standard for laboratory sustainability best practices, across all of its laboratories and manufacturing suites. This milestone reflects a company-wide effort to embed sustainable practices across Forge's operation, reinforcing its commitment to operational excellen...

University of Pittsburgh

Apr 22nd, 2026

Innovation Institute Reports Record Number of Invention Disclosures, Despite Pandemic

From swimming devices to rare disease gene therapies, Pitt inventors never stop: The Innovation Institute reported a record 394 invention disclosures for last fiscal year, and Director Evan Facher says another robust year is ahead.

Contract Pharma

Mar 3rd, 2026

Progeria Research Foundation, Forge Biologics Enter Gene Therapy Mfg. Pact

Progeria Research Foundation, Forge Biologics enter gene therapy mfg. Pact. Forge Biologics will provide process development and manufacturing services to support gene therapy for ultrarare disease. March 3, 2026 Managing Editor, Contract Pharma The Progeria Research Foundation (PRF), a research organization developing treatments for Hutchinson-Gilford Progeria Syndrome, and Forge Biologics, a manufacturer of gene therapies, entered a manufacturing agreement to support the development and manufacture of SamPro-2, PRF's investigational gene therapy for adolescence with Progeria, an ultrarare and fatal genetic disease characterized by rapid aging. The manufacturing agreement leverages PRF's research-driven Progeria program with Forge's integrated gene therapy capabilities including process development, cGMP manufacturing, FUEL platform technologies, and regulatory consultation. Forge will provide manufacturing services for Investigative New Drug (IND)-enabling studies with SamPro-2, a gene therapy that uses adeno-associated virus (AAV), a commonly utilized delivery vehicle in gene therapy, to deliver a base editing approach designed to correct the single DNA base mutation in the lamin A gene that causes Progeria. "Behind every program like this are patients and families who have waited a long time for progress," said John Maslowski, president and chief executive officer of Forge Biologics. "The Progeria Research Foundation and its Gene Team have shown extraordinary dedication to advancing this science, and we are honored to partner with them. At Forge, we bring that same level of care, expertise, and technical rigor to our manufacturing work as we help advance this program for patients."

PharmaSource

May 15th, 2025

Forge Biologics Partners with Fractyl Health on AAV Manufacturing for Metabolic Gene Therapy

Forge Biologics partners with Fractyl Health on AAV manufacturing for metabolic gene therapy.

Forge Biologics

GMP Equipment Monitoring Technician

About the job